TY  - JOUR
AU  - Scuteri, Damiana
AU  - Tonin, Paolo
AU  - Nicotera, Pierluigi
AU  - Bagetta, Giacinto
AU  - Corasaniti, Maria Tiziana
TI  - Real world considerations for newly approved CGRP receptor antagonists in migraine care.
JO  - Expert review of neurotherapeutics
VL  - 22
IS  - 3
SN  - 1473-7175
CY  - Abingdon
PB  - Taylor & Francis Group
M1  - DZNE-2022-00498
SP  - 221 - 230
PY  - 2022
AB  - Migraine is the leading cause of years lived with disability in people under 50. Electrophysiological phenomena at the basis of prodromal and headache attack phases and of chronification processes involve calcitonin-gene related peptide (CGRP) as a fundamental player become a game changer of migraine pharmacotherapy.The purpose of the present review is to retrace fundamental stages of CGRP from its discovery to the role in migraine pathogenesis and therapy to underscore the change of paradigm offered by the newly approved small molecules to antagonize CGRP receptor, the gepants. In particular, the development of this new class is gone over from the initial synthesis of C-terminus truncated CGRP antagonists to the development of the first generation of gepants ending with Zavegepant that can be considered the third generation.The history of CGRP in migraine draws the successful road to follow for key signaling pathways of modulation of nociceptive facilitation by diencephalic and brainstem nuclei, including dopaminergic neurotransmission, orexin A and the large-conductance calcium-activated potassium (BKCa) and ATP-sensitive potassium (KATP) channels also investigating the potential of essential oils and the role of polymorphisms. Real-world post marketing long-term data are needed for gepants.
KW  - Calcitonin Gene-Related Peptide
KW  - Calcitonin Gene-Related Peptide Receptor Antagonists: pharmacology
KW  - Calcitonin Gene-Related Peptide Receptor Antagonists: therapeutic use
KW  - Headache: drug therapy
KW  - Humans
KW  - Migraine Disorders: drug therapy
KW  - Migraine Disorders: metabolism
KW  - Receptors, Calcitonin Gene-Related Peptide
KW  - Atogepant (Other)
KW  - CGRP antagonists (Other)
KW  - gepants (Other)
KW  - migraine (Other)
KW  - rimegepant (Other)
KW  - ubrogepant (Other)
KW  - vazegepant (Other)
KW  - Calcitonin Gene-Related Peptide Receptor Antagonists (NLM Chemicals)
KW  - Receptors, Calcitonin Gene-Related Peptide (NLM Chemicals)
KW  - Calcitonin Gene-Related Peptide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:35240905
DO  - DOI:10.1080/14737175.2022.2049758
UR  - https://pub.dzne.de/record/163759
ER  -